ArticleFrontiers in endocrinology2026
Effect modification by fatty liver in the association between triglyceride-Glucose index and new-onset hypertension: a large health-examination cohort study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The triglyceride-glucose (TyG) index is a simple surrogate marker of insulin resistance. Whether baseline fatty liver modifies the association between TyG and incident hypertension has not been evaluated in large longitudinal cohorts. Methods: This retrospective cohort study included 66,664 adults without hypertension at baseline who underwent routine health examinations and follow-up. The TyG index was calculated from fasting triglyceride and fasting glucose concentrations and analyzed as both a continuous and categorical variable. Baseline fatty liver status was assessed by abdominal ultrasonography. Participants were followed for a median of 2.37 years (interquartile range, 1.69-3.21 years). Multivariable Cox proportional hazards models adjusted for age, sex, marital status, ethnicity, body mass index, lifestyle factors, cholesterol measures, and liver enzymes were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Effect modification by fatty liver status was evaluated using stratified analyses and a TyG-by-fatty liver interaction term. Joint associations of TyG category and fatty liver status with new-onset hypertension were also examined. Results: During follow-up, 13,949 (20.9%) participants developed new-onset hypertension. Higher TyG was independently associated with new-onset hypertension as a continuous variable (HR 1.37, 95% CI 1.30-1.45) and in the highest versus lowest quartile (HR 1.61, 95% CI 1.49-1.75). Participants with both high TyG and fatty liver had the highest risk (HR 1.63, 95% CI 1.52-1.76), and fatty liver significantly modified the TyG-hypertension association (P for interaction <0.001). These associations remained materially unchanged in sensitivity analyses with additional adjustment for family history of hypertension, diabetes status, kidney function, and baseline blood pressure. Conclusions: Higher baseline TyG and fatty liver were associated with an increased risk of new-onset hypertension. Baseline fatty liver modified the association between TyG and new-onset hypertension. These findings may help inform the interpretation of TyG-related future hypertension risk according to baseline fatty liver status among adults undergoing routine health examinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.